Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.
Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.
复制标题
DOI：
10.1186/s40168-018-0483-7
复制
发表时间：
2018-05-22
期刊：
影响因子：
15.5
通讯作者：
Pazienza V
中科院分区：
文献类型：
--
作者：
Panebianco C;Andriulli A;Pazienza V
癌症是世界范围内的主要健康负担，尽管医学疗法不断进步，但对标准药物的耐药性和不良反应仍然是治疗失败的重要原因。越来越多的证据表明，肠道细菌可以通过调节疗效或毒性来影响对化疗和免疫药物的反应。此外，肿瘤内细菌已被证明可以调节化疗反应。同时，抗癌治疗本身会显著影响微生物群的组成，从而破坏体内平衡并加剧患者的不适。在这里，我们回顾了有关微生物群在介导化疗和免疫治疗疗效和毒性中的作用以及这些治疗选择触发导致副作用严重程度的生态失调状况的能力的现有知识。此外，我们讨论了使用益生菌，益生元，合生元，益生元和抗生素作为新兴的策略来操纵微生物群，以改善治疗结果或至少确保患者在抗癌治疗的所有沿着更好的生活质量。
Cancer is a major health burden worldwide, and despite continuous advances in medical therapies, resistance to standard drugs and adverse effects still represent an important cause of therapeutic failure. There is a growing evidence that gut bacteria can affect the response to chemo- and immunotherapeutic drugs by modulating either efficacy or toxicity. Moreover, intratumor bacteria have been shown to modulate chemotherapy response. At the same time, anticancer treatments themselves significantly affect the microbiota composition, thus disrupting homeostasis and exacerbating discomfort to the patient. Here, we review the existing knowledge concerning the role of the microbiota in mediating chemo- and immunotherapy efficacy and toxicity and the ability of these therapeutic options to trigger dysbiotic condition contributing to the severity of side effects. In addition, we discuss the use of probiotics, prebiotics, synbiotics, postbiotics, and antibiotics as emerging strategies for manipulating the microbiota in order to improve therapeutic outcome or at least ensure patients a better quality of life all along of anticancer treatments.
登录
查看更多内容
PD-1和PD-L1检查点信号传导抑制癌症免疫疗法：机制，组合和临床结果。
影响因子：
5.6
作者：
Alsaab HO;Sau S;Alzhrani R;Tatiparti K;Bhise K;Kashaw SK;Iyer AK
通讯作者：
Iyer AK
影响因子：
64.8
作者：
Arumugam, Manimozhiyan;Raes, Jeroen;Pelletier, Eric;Le Paslier, Denis;Yamada, Takuji;Mende, Daniel R.;Fernandes, Gabriel R.;Tap, Julien;Bruls, Thomas;Batto, Jean-Michel;Bertalan, Marcelo;Borruel, Natalia;Casellas, Francesc;Fernandez, Leyden;Gautier, Laurent;Hansen, Torben;Hattori, Masahira;Hayashi, Tetsuya;Kleerebezem, Michiel;Kurokawa, Ken;Leclerc, Marion;Levenez, Florence;Manichanh, Chaysavanh;Nielsen, H. Bjorn;Nielsen, Trine;Pons, Nicolas;Poulain, Julie;Qin, Junjie;Sicheritz-Ponten, Thomas;Tims, Sebastian;Torrents, David;Ugarte, Edgardo;Zoetendal, Erwin G.;Wang, Jun;Guarner, Francisco;Pedersen, Oluf;de Vos, Willem M.;Brunak, Soren;Dore, Joel;Weissenbach, Jean;Ehrlich, S. Dusko;Bork, Peer
通讯作者：
Bork, Peer
DOI：
10.1016/j.uct.2007.11.003
发表时间：
2008-03-01
期刊：
Update on cancer therapeutics
影响因子：
--
作者：
Jahrsdorfer, Bernd;Weiner, George J
通讯作者：
Weiner, George J
影响因子：
16.6
作者：
Dubin K;Callahan MK;Ren B;Khanin R;Viale A;Ling L;No D;Gobourne A;Littmann E;Huttenhower C;Pamer EG;Wolchok JD
通讯作者：
Wolchok JD
影响因子：
3
作者：
Forsgård RA;Marrachelli VG;Korpela K;Frias R;Collado MC;Korpela R;Monleon D;Spillmann T;Österlund P
通讯作者：
Österlund P